Turn Therapeutics Inc. Common Stock Total Assets
Turn Therapeutics Inc. Common Stock total assets. Based on the latest financial reports, Turn Therapeutics Inc. Common Stock (TTRX) holds total assets worth $16.96 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of Turn Therapeutics Inc. Common Stock for the company's overall valuation and market capitalisation.
Total Assets of Turn Therapeutics Inc. Common Stock (2023–2025)
Total assets of Turn Therapeutics Inc. Common Stock from 2023 to 2025. This chart illustrates how Turn Therapeutics Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See Turn Therapeutics Inc. Common Stock stock quote for real-time trading data and today's change.
Turn Therapeutics Inc. Common Stock - Asset Composition Analysis
Turn Therapeutics Inc. Common Stock Total Assets Breakdown (December 2025)
Turn Therapeutics Inc. Common Stock total assets breakdown as of December 2025. Turn Therapeutics Inc. Common Stock's total assets of $16.96 Million consist of 42.7% current assets and 57.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 41.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $922.17K | 7.6% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2023–2025)
This chart illustrates how Turn Therapeutics Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Turn Therapeutics Inc. Common Stock's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Turn Therapeutics Inc. Common Stock's current assets represent 42.7% of total assets in 2025, a decrease from 59.7% in 2023.
- Cash Position: Cash and equivalents constituted 41.7% of total assets in 2025, down from 58.7% in 2023.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, a decrease from 38.0% in 2023.
- Asset Diversification: The largest asset category is intangible assets at 7.6% of total assets.
Turn Therapeutics Inc. Common Stock Competitors by Total Assets
Key competitors of Turn Therapeutics Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Turn Therapeutics Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.19 | 3.20 | 3.20 |
| Quick Ratio | 1.19 | 3.20 | 3.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.66 Million | $2.33 Million | $2.33 Million |
Turn Therapeutics Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Turn Therapeutics Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 434.15 |
| Latest Market Cap to Assets Ratio | 23.75 |
| Asset Growth Rate (YoY) | 493.6% |
| Total Assets | $12.16 Million |
| Market Capitalization | $288.80 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Turn Therapeutics Inc. Common Stock's assets at a significant premium (23.75x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Turn Therapeutics Inc. Common Stock's assets grew by 493.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Turn Therapeutics Inc. Common Stock (2023–2025)
The table below shows the annual total assets of Turn Therapeutics Inc. Common Stock from 2023 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $12.16 Million | +493.60% |
| 2024-12-31 | $2.05 Million | +1.75% |
| 2023-12-31 | $2.01 Million | -- |
About Turn Therapeutics Inc. Common Stock
Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and de… Read more